Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target
Insilico Medicine (“Insilico”), a clinical stage artificial intelligence (AI)-driven drug R&D company, today announces positive topline results of safety,
Source: einnews.com